IP Verse

Compositions For Preventing And/Or Treating Pathological Conditions Associated With Alpha-Glucosidase - EP3107556

The patent EP3107556 was granted to Universit Blaise Pascal Clermont II on Apr 10, 2019. The application was originally filed on Feb 18, 2015 under application number EP15709276A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3107556

UNIVERSIT BLAISE PASCAL CLERMONT II
Application Number
EP15709276A
Filing Date
Feb 18, 2015
Status
Granted And Under Opposition
Mar 8, 2019
Publication Date
Apr 10, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ARLA FOODS AMBAJan 7, 2020PLOUGMANN VINGTOFTADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTEP1661909
INTERNATIONAL-SEARCH-REPORTEP1690869
INTERNATIONAL-SEARCH-REPORTUS2004229934
INTERNATIONAL-SEARCH-REPORTUS2006035864
INTERNATIONAL-SEARCH-REPORTWO2006005757
INTERNATIONAL-SEARCH-REPORTWO2006084560
OPPOSITIONEP3107556
OPPOSITIONJP2003024012
OPPOSITIONWO2012085266

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- GAD, "Solid dosage forms", Pharmaceutical Manufacturing Handbook - Production and Processes, (20080000), page 236, XP055664770
OPPOSITION- MARUYAMA et al., "Studies on the active site and antihypertensive activity of angiotensin I-Converting enzyme inhibitors derived from casein", Agric Biol Chem, (19870000), vol. 51, no. 6, pages 1581 - 1586, XP009117912
OPPOSITION- POWER et al., "Food protein hydrolysates as a source of dipepetidyl peptidase IV inhibitory peptides for the management of type 2 diabetes", Proc Nutr Soc, vol. 73, (20131017), pages 34 - 43, XP055664766
OPPOSITION- HATANAKA et al., "Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran", Food Chem, (20120000), vol. 134, no. 2, pages 797 - 802, XP028417765
OPPOSITION- GU et al., "- Angiotensin I-converting enzyme inhibitory activity of low-molecular-weight peptides from Atlantic salmon (L.) skin", Food Res Int, (20110000), vol. 44, pages 1536 - 1540, XP028223348
OPPOSITION- Geng Deng-feng; Jin Dong-mei; Wu Wei; Liang Yong-de; Wang Jing-feng, "Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: A meta-analysis of 72,128 patients", International Journal of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20120717), vol. 167, no. 6, doi:10.1016/j.ijcard.2012.06.125, ISSN 0167-5273, pages 2605 - 2610, XP028707298
OPPOSITION- Abuissa, H. Jones, P.G. Marso, S.P. O'Keefe, J.H., "Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes", Journal of the American College of Cardiology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20050906), vol. 46, no. 5, doi:10.1016/j.jacc.2005.05.051, ISSN 0735-1097, pages 821 - 826, XP005051000
OPPOSITION- LACROIX et al., "Inhibition of dipeptidyl peptidase (DPP) and a-glucosidase activities by pepsin-treated whey proteins", J Agric Food Chem, (20130000), vol. 61, pages 7500 - 7506, XP055664710
OPPOSITION- OKI et al., "Inhibitory effect of a-glucosidase inhibitors varies according to its origin", J Agric Food Chem, (19990000), vol. 47, pages 550 - 553, XP055664758
OPPOSITION- CHIBA, "Molecular mechanism in a-glucosidase and glucoamylase", Bioscience, Biotechnology, Biochemistry, (19970000), vol. 61, no. 8, pages 1233 - 1239, XP055664704
OPPOSITION- Gillespie Effie L, White C Michael; Kardas Michael; Lindberg Michael; Coleman Craig I, "The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, US , (20050901), vol. 28, no. 9, doi:10.2337/diacare.28.9.2261, ISSN 0149-5992, pages 2261 - 2266, XP093172662
OPPOSITION- Ramos-Nino Maria E, Blumen Steven R; , "Benefits of ACE Inhibitors in Diabetes", Clinical Medicine. Therapeutics, (20090101), vol. 1, doi:10.4137/CMT.S2027, ISSN 1179-1713, page CMT.S2027, XP093172666

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents